01250nas a2200313   4500000000100000008004100001260001500042653003400057653003000091653002000121653001400141100001600155700001900171700002700190700001800217700001500235700001800250700002000268700002600288700001900314700002100333700001800354245012800372856004700500300000800547490000700555520036000562022001400922       2025                            d  c2025-05-2310aCancer-associated fibroblasts10aEsophageal adenocarcinoma10aorgan-on-a-chip10aorganoids1 aSanjima Pal1 aElee Shimshoni1 aSalvador Flores Torres1 aMingyang Kong1 aKulsum Tai1 aVeena Sangwan1 aNicholas Bertos1 aSwneke Donovan Bailey1 aJulie Bérubé1 aDonald E. Ingber1 aLorenzo Ferri00aPatient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology  uhttps://doi.org/10.1186/s12967-025-06593-1  a5770 v233 aEsophageal adenocarcinoma (EAC) is the sixth most deadly cancer worldwide, with increasing incidence in North America. As no targeted therapy or immunotherapy has revolutionized the management of EAC, chemotherapy is the only standard of care. Most patients with EAC experience poor outcomes because of the inherent or acquired resistance to chemotherapy.  a1479-5876